Randomized, double-blind, placebo-controlled single ascending dose study to assess the safety and tolerability of AP30663 in healthy subjects
Phase of Trial: Phase I
Latest Information Update: 05 Nov 2018
At a glance
- Drugs AP-30663 (Primary)
- Indications Atrial fibrillation
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors Acesion Pharma
- 05 Nov 2018 According to an Acesion Pharma media release, company announces positive results from this study.
- 05 Nov 2018 Results published in the Media Release
- 12 Mar 2018 According to an Acesion Pharma media release, data expected by the end of August 2018.